RxDoctor Payments Data

Kimberly Berni, MD

Urology · Saint Peters, MONPI 1245289677

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,517 of the $14,129 with a category attached, or 60.3%. 47 manufacturers reported payments, led by Astellas Pharma US Inc at 48.3% of the total. Reporting peaked in 2019 at $4,491 and has fallen 61.1% since, to $1,747 in 2025.

$14,129in general payments, 2019–2025

Across 283 payments — averaging $49.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$7K
  • Boston Scientific$851
  • Stryker$786
  • Teleflex LLC$773
  • Axonics, Inc.$408
  • Pfizer$390
  • plus $4K from 41 others

What the payments were for

  • Speaking & faculty fees$5,51039%
  • Travel & lodging$150%
  • Food & beverage$8,51760%
  • Education$871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,129 in reported general payments places this provider in the 85th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$132,239
Medicare patients
432
Services billed
4,052

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron234$194,433
Mirabegron ErMirabegron44$31,950
Estradiol364$22,467
Solifenacin Succinate191$7,009
Finasteride602$6,974
Oxybutynin Chloride ErOxybutynin Chloride294$6,013
Tamsulosin Hcl481$5,662
Methenamine Hippurate45$4,536
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst103$3,713
Trospium Chloride80$3,629
Cephalexin298$3,506
Potassium Citrate ErPotassium Citrate36$3,113
Bethanechol Chloride46$2,169
Desmopressin Acetate24$2,116
Tolterodine Tartrate13$1,934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$6,828$194,433234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 urology providers in Missouri.

Other urology in Saint Peters

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →